Sunho Biologics Reports 6-Month Loss of RMB38.2 Million, Slight Increase from Previous Year
Sunho Biologics Inc. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a net loss of RMB38.199 million, an increase from the RMB36.077 million loss in the same period in 2024. Other income saw a significant rise to RMB5.035 million from RMB1.782 million in the previous year. However, there was a notable decrease in other gains and losses, net, which fell to a negative RMB963,000 from a positive RMB38.720 million in 2024. Research and development expenses decreased to RMB28.767 million from RMB37.708 million, and administrative expenses were reduced to RMB12.678 million compared to RMB15.270 million in the prior year. Financial costs increased slightly to RMB826,000 from RMB566,000. The company did not incur any listing expenses during this period, a change from the RMB23.055 million recorded in 2024. The group's total cash and cash equivalents increased significantly from RMB79 million as of December 31, 2024, to RMB171 million as of June 30, 2025. No income tax expense was incurred, and no dividends were declared or proposed for this interim period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.